The manufacturer of a linear accelerator (LINAC) has reported that the target melting phenomenon could be caused by a non-recommended output setting and the excessive use of monitor unit (MU) with intensity-modulated radiation therapy (IMRT). Due to these reasons, we observed an unexpected beam interruption during the treatment of a patient in our institution. The target status was inspected and a replacement of the target was determined. After the target replacement, the beam profile was adjusted to the machine commissioning beam data, and the absolute doses-towater for 6 MV and 10 MV photon beams were calibrated according to American Association of Physicists in Medicine (AAPM) Task Group (TG)-51 protocol. To verify the beam data after target replacement, the beam flatness, symmetry, output factor, and percent depth dose (PDD) were measured and compared with the commissioning data. The difference between the referenced and measured data for flatness and symmetry exhibited a coincidence within 0.3% for both 6 MV and 10 MV, and the difference of the PDD at 10 cm depth (PDD 10 ) was also within 0.3% for both photon energies. Also, patient-specific quality assurances (QAs) were performed with gamma analysis using a 2-D diode and ion chamber array detector for eight patients. The average gamma passing rates for all patients for the relative dose distribution was 99.1%±1.0%, and those for absolute dose distribution was 97.2%±2.7%, which means the gamma analysis results were all clinically acceptable. In this study, we recommend that the beam characteristics, such as beam profile, depth dose, and output factors, should be examined. Further, patient-specific QAs should be performed to verify the changes in the overall beam delivery system when a target replacement is inevitable; although it is more important to check the beam output in a daily routine.
In this study, we performed the beam verification to validate the clinically acceptable machine performance after the target replacement. Also, we measured beam flatness, symmetry, output factor, and PDD after fine beam adjustment, also a patient-specific quality assurance (QA)
analysis for the end-to-end machine performance verification was performed. [1] [2] [3] Safety issue caused by the activated target was carefully concerned.
Materials and Methods

Beam tuning
After the target assembly replacement, the beam pro- 
Verification
According to the manufacturers beam commissioning were compared with reference data.
The patient-specific QA is the procedure to verify the coincidence between measurement and calculated dose distribution for IMRT plans by using gamma analysis. 
Results
Beam tuning
As shown in Fig. 2 , the maximum deviations of the beam profile were adjusted within 0.77% and 0.94% and field width differences were 0.32 mm and 0.07 mm for 6 MV and 10 MV, respectively.
When the beam output of each energy was adjusted to deliver 1 cGy/MU with reference conditions (SSD of 100 cm, field size of 10×10 cm 2 , and at d max ), the output deviation between before and after target replacement was 6.78% and 2.66% for 6 MV and 10 MV, respectively.
Verification
As shown in Table 1 , the differences in PDD 10 between reference and measurement were less than 0.3% for both 6 MV and 10 MV. As presented in Fig. 3 for PDD comparison with a field size of 10×10 cm 2 , the differences at d max between measurement and reference data were less than 0.5 mm and 0.7 mm and the PDD 10 were 0.04%, 0.22% for 6 MV and 10 MV, respectively.
The profile coincidences were compared with flatness and symmetry, and results were provided in Table 2 . For 6 MV, the flatness and symmetry showed good coincidence for 6×6 cm 2 , 10×10 cm 2 , and 20×20 cm 2 showing less difference than 0.3% and 0.5%, while those for 3×3 cm 2 were slightly higher showing −0.7% and −0.6%, respectively. For 10 MV, the differences were less than −0.4% and −0.5%, while those for 3×3 cm 2 were slightly higher showing −0.8% and −0.8%, respectively. Table 3 showed the output factors for various field Table 4 .
Discussion
After the target assembly replacement, the beam output was tuned and the absolute dose calibration was performed according to AAPM TG-51 protocol. The beam was steered to the reference beam data. All verification parameters such as the profile, PDD and output factor were within tolerance level based on AAPM TG-142 protocol and recommended manufacturer's guidance. 7, 8) The gamma passing rates for 8 patients after the target replacement were 97.2%±2.7% for absolute dose distribution, and 99.1%±1.0% for relative dose distribution, respectively.
Li et al. 9) reported the impact of detector types in gamma passing rates with a diode-based array (MapCHECK2) and an ion chamber-based array (MatriXX) detector for the QA of IMRT treatment plans. It has shown that they obtained outstanding gamma passing rates for both detector arrays when compared with the dose distribution of the treatment planning system for three IMRT fields. For gamma passing rate, many radiation oncology clinics have commonly employed 3%/3 mm with a threshold level of 10%, which [10] [11] [12] In this regards, our patient-specific QA summary turned out to be clinically acceptable even after the target replacement with fine adjustments.
Another consideration is about radiation safety. The possible Linac target activation should be carefully surveyed.
The removed target became a radioactive material due to prolonged exposure to the radiation, and we measured We verified the fundamental beam parameters that agreed within 1% with the reference beam data after the target assembly replacement. The gamma analysis results for eight patients with relative and absolute dose distribution were also acceptable. 13) This study suggests the prevention of the target assemblies; the beam output should be verified with daily routine, and furthermore, calibrated under the recommended conditions, i.e., depth at dose maximum not with 10 cm.
14)
Conclusion
We experienced the photon beam degradation due to the target burning, and thereby the target replacement and the beam verification were performed. We concluded that the patient treatment could be appropriately performed after the target replacement owing to guaranteed mandatory beam characteristics, and acceptable patient-specific QA results. We suggest the compliance with the manufacturer's recommendation for output calibration, i.e. at a depth of maximum dose, not at 10 cm, and the number of IMRT treatments should be controlled for the machine performance. When experiencing the undesired target puncture, beam output, profiles, and energy should be finely adjusted to the reference beam data, and patient-specific QA should be performed for validation. We also recommended that the replaced target should be kept in radiation shielded space, and the activation level should be recorded in a periodic routine.
